The fact that migraine therapy is changing is also reflected in the recent publication of the updated S1 guideline “Treatment of migraine attacks and prophylaxis of migraine”. Although triptans are still the standard medication for treating acute migraine attacks, new active ingredients are expanding the treatment arsenal. Progress has also been made in migraine prophylaxis – for example, two new oral CGRP receptor antagonists have established themselves as treatment alternatives. These are just some of the innovations that should contribute to optimized care for migraine patients.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
- InFo NEUROLOGIE & PSYCHIATRIE
Related Topics
You May Also Like
- Ataxias
Friedreich’s ataxia: when the energy metabolism attacks the nervous system
- Risk of osteoporosis in autoimmune liver diseases
Always determine bone density in PBC, PSC and AIH
- Case report: Complication after type 2 diabetes
Topical corticosteroids lead to ketoacidosis
- NSCLC
Bispecific antibodies for rare EGFR mutations
- Type 2 diabetes - glycemic control and prevention of secondary diseases
Utilizing pleiotropic cardio- and nephroprotective effects of SGLT-2-i and GLP-1-RA
- Subsyndromal anxiety disorders: Family doctor as first point of contact
Practical recommendations for diagnostics and therapy
- Patient-centered rounds in medicine
Aligning care with the patient
- Restless legs syndrome in children